Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells

Molecular Pharmacology

Volumn 71, Issue 1, 2007, Pages 101-111

  Peng, Xiang Hong ^a   Karna, Prasanthi ^a   O'Regan, Ruth M ^a   Liu, XiuJu ^a   Naithani, Rajesh ^b   Moriarty, Robert M ^b   Wood, William C ^a   Lee, Ho Young ^c   Yang, Lily ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DEGUELIN; DOCETAXEL; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; DNA PRIMERS; DOWN-REGULATION; FEMALE; GENES, REPORTER; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROTENONE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33845885778     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.027367     Document Type: Article

References (36)

1. Altieri DC (2003a) Survivin and apoptosis control. Adv Cancer Res 88:31-52.
2. Altieri DC (2003b) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54.
3. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, and Sato N (2005) Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65:11018-11025.
4. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, and Watanabe N (2000) Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204-1209.
5. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simoes-Wust AP, Yousefi S, Simon HU, Stahel R, and Zangemeister-Wittke U (2005) Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 117:755-763.
6. Chun KH, Kosmeder JW 2nd, Sun S, Pezzuto JM, Lotan R, Hong WK, and Lee HY (2003) Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 95:291-302.
7. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK, and Cheng JQ (2004) Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279:5405-5412.
8. Deveraux QL and Reed JC (1999) IAP family proteins-suppressors of apoptosis. Genes Dev 13:239-252.
9. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al. (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279:34087-34090.
10. Fang JY and Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6:322-327.
11. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876-885.
12. Fry MJ (2001) Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 3:304-312.
13. Gerhauser C, Lee SK, Kosmeder JW, Moriarty RM, Hamel E, Mehta RG, Moon RC, and Pezzuto JM (1997) Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Cancer Res 57:3429-3435.
14. Hail N Jr and Lotan R (2004) Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics. Apoptosis 9:437-447.
15. Holcik M, Gibson H, and Korneluk RG (2001) XIAP: apoptotic brake and promising therapeutic target. Apoptosis 6:253-261.
16. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, and Wu H (2001) Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104:781-790.
17. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, and Muller WJ (2001) Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21:2203-2212.
18. Igney FH and Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277-288.
19. Ikeguchi M, Nakamura S, and Kaibara N (2002) Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment. Oncol Rep 9:1121-1126.
20. Lee HY (2004) Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells. Biochem Pharmacol 68:1119-1124.
21. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, Moriarty RM, et al. (2005) Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97:1695-1699.
22. F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, and Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (Lond) 396:580-584.
23. 2/M arrest. J Biol Chem 279:15196- 15203.
24. Liston P, Young SS, Mackenzie AE, and Korneluk RG (1997) Life and death decisions: the role of the IAPs in modulating programmed cell death. Apoptosis 2:423-441.
25. Mesri M, Wall NR, Li J, Kim RW, and Altieri DC (2001) Cancer gene therapy using a survivin mutant adenovirus. J Clin Investig 108:981-990.
26. Murillo G, Salti GI, Kosmeder JW 2nd, Pezzuto JM, and Mehta RG (2002) Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer 38:2446-2454.
27. Peng XH, Cao ZH, Xia JT, Carlson GW, Lewis MM, Wood WC, and Yang L (2005) Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res 65:1909-1917.
28. Reed JC (1999) Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11:68-75.
29. Reed JC (2001) Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med 7:314-319.
30. Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, Sun TT, and Altieri DC (2005) A survivin gene signature predicts aggressive tumor behavior. Cancer Res 65:3531-3534.
31. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, et al. (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5:25-35.
32. Slee EA, Adrain C, and Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276:7320-7326, 2001.
33. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, and Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315-5320.
34. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, and Tanigawa N (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134.
35. Udeani GO, Zhao GM, Shin YG, Kosmeder JW 2nd, Beecher CW, Kinghorn AD, Moriarty RM, Moon RC, and Pezzuto JM (2001) Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats. Cancer Chemother Pharmacol 47:263-268.
36. Yang L, Cao Z, Yan H, and Wood WC (2003) Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 63:6815-6824.